Соединенные Штаты - английский - NLM (National Library of Medicine)

par pharmaceutical, inc. - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 500 mg - sodium phenylbutyrate tablets is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of the dosage and administration section.) previously, ne

Соединенные Штаты - английский - NLM (National Library of Medicine)

puracap laboratories, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 4.1 meq in 1 g - sodium polystyrene sulfonate powder, for suspension is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate powder, for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate powder, for suspension is contraindicated in patients with the following conditions: ● hypersensitivity to polystyrene sulfonate resins ● obstructive bowel disease ● neonates with reduced gut motility risk summary sodium polystyrene sulfonate powder, for suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate powder, for suspension is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients,

Соединенные Штаты - английский - NLM (National Library of Medicine)

general injectables & vaccines, inc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 234 mg in 30 ml - sodium chloride injection, usp, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patents who have special problems of sodium electrolyte intake or excretion. it is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. after available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from sodium chloride injection, usp, 23.4% and diluted for use. sodium chloride injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. isotonic sodium chloride injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. the toxic symptoms that follow various form

Соединенные Штаты - английский - NLM (National Library of Medicine)

belcher pharmaceuticals, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. sodium polystyrene sulfonate for suspension is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates (see precautions).

Соединенные Штаты - английский - NLM (National Library of Medicine)

sunrise pharmaceutical, inc. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. limitation of use : sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2) ] sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the pract

Соединенные Штаты - английский - NLM (National Library of Medicine)

eci pharmaceuticals, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1meq po

Соединенные Штаты - английский - NLM (National Library of Medicine)

epic pharma, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 4.1 meq in 1 g - sodium polystyrene sulfonate powder, for suspension is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate powder, for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate powder, for suspension is contraindicated in patients with the following conditions: risk summary sodium polystyrene sulfonate powder, for suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate powder, for suspension is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate powder, for suspension is expected to bind potassium at the practical exchange ratio of 1meq potassium per 1 gram of resin. in neonates, sodium polystyrene sulfonate powder, for suspension should not be given by the oral route. in both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with sodium polystyrene sulfonate powder, for suspension use [see warnings and precautions (5.4)] .

Соединенные Штаты - английский - NLM (National Library of Medicine)

atlantic biologicals corp - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 1 g in 1 g - sodium polystyrene sulfonate, usp is indicated for the treatment of hyperkalemia. sodium polystyrene sulfonate, usp is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates (see precautions).

Соединенные Штаты - английский - NLM (National Library of Medicine)

cmp pharma, inc. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 1 g in 1 g - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate for suspension is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate for suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate for suspension is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfona

Соединенные Штаты - английский - NLM (National Library of Medicine)

hospira, inc. - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20, sodium cation - unii:lyr4m0nh37) - sodium bicarbonate 42 mg in 1 ml - sodium bicarbonate injection, usp is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. but since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total co2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. sodium bicarbonate injection, usp is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction, and in patients receiving diuretics known to produce a hypochloremic alkalosis.